Bedel Financial Consulting’s GSK GSK Stock Holding History

Bedel Financial Consulting’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$396K	Hold	7,562	–	–	0.04%	209
2026 Q1	$417K	Hold	7,562	–	–	0.05%	184
2025 Q4	$371K	Hold	7,562	–	–	0.04%	195
2025 Q3	$326K	Hold	7,562	–	–	0.04%	206
2025 Q2	$290K	Hold	7,562	–	–	0.04%	217
2025 Q1	$284K	Hold	7,562	–	–	0.04%	215
2024 Q4	$285K	Sell	7,562 -11	-0.1%	-$396	0.04%	215
2024 Q3	$310K	Buy	7,573 +11	+0.1%	+$450	0.04%	205
2024 Q2	$291K	Hold	7,562	–	–	0.04%	200
2024 Q1	$324K	Hold	7,562	–	–	0.05%	185
2023 Q4	$280K	Buy	7,562 +676	+10%	+$24.3K	0.05%	194
2023 Q3	$250K	Hold	6,886	–	–	0.05%	196
2023 Q2	$245K	Buy	6,886 +396	+6%	+$14.2K	0.05%	203
2023 Q1	$231K	Buy	+6,490	New	+$227K	0.06%	200
2022 Q2	–	Sell	-166	Closed	-$9K	–	464
2022 Q1	$9K	Buy	166 +123	+286%	+$6.68K	﹤0.01%	688
2021 Q4	$2K	Buy	+43	New	+$2.24K	﹤0.01%	884
2019 Q2	–	Sell	-40	Closed	-$2K	–	732
2019 Q1	$2K	Hold	40	–	–	﹤0.01%	642
2018 Q4	$2K	Hold	40	–	–	﹤0.01%	607
2018 Q3	$1K	Hold	40	–	–	﹤0.01%	647
2018 Q2	$2K	Hold	40	–	–	﹤0.01%	615
2018 Q1	$2K	Buy	+40	New	+$1.86K	﹤0.01%	607

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bedel Financial Consulting's GSK Position: Q2 2026 in Review

Bedel Financial Consulting held its GSK (GSK) position steady in Q2 2026 at 7,562 shares worth $396K. The position accounts for 0.04% of the portfolio, ranked #209.

Bedel Financial Consulting first reported a position in GSK in Q1 2018 and has held it in 21 quarters since. The position peaked at $417K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bedel Financial Consulting held 7,562 shares of GSK worth $396K as of Q2 2026.
Bedel Financial Consulting left its GSK share count unchanged in Q2 2026.
GSK made up 0.04% of Bedel Financial Consulting's portfolio in Q2 2026, its #209 holding.
Bedel Financial Consulting first reported a position in GSK in Q1 2018 and has held it in 21 quarters since.
Bedel Financial Consulting's GSK position peaked at $417K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bedel Financial Consulting's 13F filing for Q2 2026, filed 29 Jul 2026.